Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus SEVELAMER HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus SEVELAMER HYDROCHLORIDE.
AURYXIA vs SEVELAMER HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Category C
Category A/B
Phosphate Binder
Phosphate Binder